What SageMedic does

SageMedic Corp. is a Redwood City, California-based CLIA-certified clinical laboratory (CLIA ID: 05D2236809, accredited by COLA and CMS) that develops and commercializes the SAGE Oncotest™, an ex-vivo functional profiling assay for solid tumor treatment decision support. The test processes fresh cancer tissue into multiple testable replicates within 24 hours and exposes those replicates to a curated panel of FDA-approved drugs, then returns laboratory drug response and resistance results to the ordering oncologist within 7-10 days. The company was founded in 2018 by Dr. Chris Apfel (CEO) and Dr. Brigitte Apfel (Co-Founder, Treasurer), both California-licensed physicians, and operates with 1-10 employees.

The product is positioned as a complement to genomic testing: whereas DNA sequencing identifies mutations, the SAGE Oncotest measures how the patient's actual tumor tissue responds to specific drugs ex-vivo, with internal validation claiming actionable laboratory information in 88% of cases compared to 26.8% for genomic testing and a meta-analysis-based claim that functional profiling makes tumors twice as likely to respond to therapy. The technology builds on published validation studies of predecessor ex-vivo Extreme Drug Resistance (EDR) assays with reported 90%+ negative predictive value. It is indicated for Stage III/IV solid tumors and is not used for early-stage or slow-growing cancers.

SageMedic generates revenue through a one-time, self-pay laboratory service fee per test; the test is not covered by insurance and pricing is not publicly disclosed. Distribution is B2B2C: physicians order the test, fresh tissue is collected at the surgical or biopsy facility and shipped to the California laboratory, and telemedicine consultations are offered only to patients physically in California at the time of service. Specimens are accepted from US physicians nationwide and from international hospitals and physicians, with consent and payment processed via DocuSign under a HIPAA Business Associate Agreement and patient screening handled through Zoho Forms.

Name

SageMedic

Legal name

SageMedic Corp.

Website

https://sagemedic.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

SageMedic Corp. operates a CLIA-certified laboratory offering the SAGE Oncotest™, an ex-vivo functional profiling assay that evaluates fresh tumor tissue against FDA-approved drugs to support oncologists' treatment decisions for Stage III/IV solid tumor patients on a self-pay basis.

Ownership category

akta.pro rank

Product category

Functional Precision Oncology Diagnostics

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Central Laboratory Services (Core Lab Operations) (HLAGAEAA)

akta.pro secondary industry

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Functional cancer profiling
• Precision oncology testing
• Ex-vivo drug response
• Tumor resistance profiling
• CLIA laboratory services

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Others

Revenue model

1. SAGE Oncotest Laboratory Testing: One-time laboratory testing service where patients pay for the test directly. The test is not covered by insurance. Physicians order the test, patients sign purchase agreements and pay for the service. Results are delivered within 7-10 days.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

SageMedic operates a CLIA-certified clinical laboratory offering the SAGE Oncotest™, an ex-vivo functional profiling assay that evaluates fresh cancer tissue samples against a curated panel of FDA-approved drugs to determine drug response and resistance patterns. Results are delivered to the ordering physician within 7-10 days to support individualized oncology treatment planning for patients with advanced solid tumors. Telemedicine consultations are also offered exclusively to patients physically located in California.

Product overview

SageMedic offers a single unified product, the SAGE Oncotest™ functional precision oncology test. This CLIA-certified laboratory service evaluates fresh tumor tissue samples against a curated panel of FDA-approved chemotherapy and targeted therapy drugs using proprietary ex-vivo laboratory techniques. The test is designed to complement genomic testing by providing functional drug response insights, helping oncologists make more informed treatment decisions for patients with advanced solid tumors. Results are delivered within 7-10 days.

Differentiator

Problem solved

Functional benefit

Brands

• SAGE Oncotest™: Functional profiling assay that evaluates how a patient's tumor tissue responds to FDA-approved drug treatments ex-vivo, providing laboratory insights to support individualized cancer treatment planning within 7-10 days.

Quantifiable outcome

• 88% actionable information rate vs 26.8% for genomic testing
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature4 records

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Caris Life Sciences: Caris offers multi-omic molecular profiling (DNA, RNA, protein) for oncology, including functional and proteomic components, serving oncologists with treatment-decision support — directly comparable to SageMedic's functional profiling service for advanced solid tumors.
• Champions Oncology: Champions provides patient-derived xenograft (PDX) and ex-vivo tumor models for drug response testing in oncology, offering a functionally analogous (though slower) precision oncology testing service targeting the same oncologist and patient population as SageMedic.
• Personalis: Personalis provides tumor-informed molecular profiling (NeXT Personal) for oncology therapy selection and recurrence monitoring, competing for oncologist ordering and precision-oncology share of wallet in advanced solid tumors.

Emerging players

• SEngine Precision Medicine: SEngine Precision Medicine runs ex-vivo functional drug screening on patient tumor samples to guide oncology treatment selection, making it one of the closest small-scale functional-profiling comparables to SAGE Oncotest.
• MI Bioresearch (part of Molecular Imaging): MI Bioresearch provides functional in-vitro and in-vivo oncology drug response testing services (including patient-derived models) for biopharma and clinical use, representing a niche functional-profiling peer with overlapping customer workflows.

Broad incumbents

• Foundation Medicine: Foundation Medicine is a leading genomic profiling company (FoundationOne CDx/FoundationOne Liquid CDx) widely used by oncologists for treatment decision support; it represents the incumbent standard-of-care approach that SageMedic positions its functional assay against.
• Tempus Labs: Tempus provides AI-enabled multi-modal precision oncology (genomic, transcriptomic, imaging) for oncologists and biopharma; it is a broad incumbent in cancer molecular profiling that competes for oncologist mindshare and ordering behavior.
• Guardant Health: Guardant Health offers liquid biopsy-based genomic profiling (Guardant360, Guardant Reveal) for advanced cancer treatment selection, addressing the same oncologist customer base and treatment-decision workflow as SageMedic.
• Natera: Natera is an established precision medicine company with oncology testing (Signatera) and a broader reproductive/oncology franchise; it competes for oncologist ordering and is a comparable reimbursement- and commercialization-driven diagnostics peer.
• Exact Sciences: Exact Sciences is a publicly-traded cancer diagnostics company (Cologuard, Oncotype) with a growing oncology menu; it is a broad incumbent competing for oncologist ordering and is a relevant comparable for a CLIA-certified cancer diagnostics commercial trajectory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SageMedic